Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

sofosbuvir

- PMLiVE

As Europe goes to polls, pharma seeks to keep healthcare, R&D a priority

Eurosceptics want to block greater EU integration

- PMLiVE

No deal or revoke looming as fourth vote on Brexit nears

Voters set to protest via EU elections, no-deal remains possibility

- PMLiVE

Europe responding to gene therapy challenge, but picture remains fragmented

Germany, Italy and England using outcomes-based deals

- PMLiVE

Brexit “having impact on EU drug development”

EMA and UK regulator both affected

- PMLiVE

European approval for Skyrizi, hot on the heels of US

Welcome news, but can't replace $20bn Humira

- PMLiVE

Gilead gets ‘gold’ in England’s hepatitis C eradication drive

NHS England's tender process drives down cost of medicines

- PMLiVE

Janssen looks to expand Darzalex in Europe

Regimen reduced risk of disease progression or death by 44%

- PMLiVE

CHMP backs Lynparza in breast cancer, Dupixent in asthma

Akcea's FDA-rejected Waylivra also recommended

EU flag

Europe’s medicines tracking system goes live

Covers 140,000 pharmacies in 28 countries

Drug launches to watch in 2019

13 market-changing drugs expected to hit the European market this year

- PMLiVE

NHS England sees off AbbVie’s Hep C legal challenge

Claims of unfair process dismissed by High Court

- PMLiVE

Europe closer to biosimilar rule change, despite fierce resistance from pharma

EFPIA says it weakens IP commitment - supporters say it will boost exports

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links